Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

VV. McLaughlin, P. Jansa, JE. Nielsen-Kudsk, M. Halank, G. Simonneau, E. Grünig, S. Ulrich, S. Rosenkranz, MA. Gómez Sánchez, T. Pulido, J. Pepke-Zaba, JA. Barberá, MM. Hoeper, JL. Vachiéry, I. Lang, F. Carvalho, C. Meier, K. Mueller, S. Nikkho,...

. 2017 ; 17 (1) : 216. [pub] 20171228

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012961

BACKGROUND: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH. METHODS: We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted therapy (n = 84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking distance (6MWD) as exploratory efficacy endpoints. RESULTS: In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean ± standard deviation 6MWD had increased by 33 ± 42 m at Week 12 with no clinically relevant differences between the switched and treatment-naïve subgroups. CONCLUSIONS: Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were switched from other PAH-targeted therapies. No new safety signals were observed. TRIAL REGISTRATION: ClinicalTrials.org NCT01784562 . Registered February 4, 2013.

Allgemeines Krankenhaus der Stadt Wien Medizinische Universität Wien Wien Austria

Bayer AG Wuppertal Germany

Cardiology and Angiology Department General University Hospital Prague Czech Republic

Clinic for Respiratory Medicine Hannover Medical School Hannover Germany

Clinic of Pulmonology University Hospital Zurich Zurich Switzerland

Département de Cardiologie Hôpital Erasme Université Libre de Bruxelles Brussels Belgium

Department 3 of Internal Medicine Cologne University Heart Center Cologne Germany

Department of Cardiological Medicine Aarhus University Aarhus Denmark

Department of Pulmonary Medicine Hospital Clínic IDIBAPS University of Barcelona and Biomedical Research Networking Center on Respiratory Diseases Madrid Spain

Division of Cardiothoracic Surgery Foundation IRCCS Policlinico San Matteo University of Pavia School of Medicine Pavia Italy

Global Clinical Development Bayer AG Berlin Germany

Global Development Bayer SA São Paulo Brazil

Global Medical Affairs Bayer AG Berlin Germany

Hôpital Bicêtre Université Paris Sud Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique and INSERM Unité 999 Paris France

Instituto Nacional de Cardiología Mexico City Mexico

National Pulmonary Vascular Diseases Unit Papworth Hospital Cambridge UK

Thoraxclinic University Hospital Heidelberg Heidelberg Germany

Unidad de 1 Cardiaca e Hipertensión Pulmonar Hospital Universitario 12 de Octubre Madrid Spain

University Hospital Dresden Dresden Germany

University of Michigan Health System 1011 Cornwell Pl Ann Arbor 48104 USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012961
003      
CZ-PrNML
005      
20190411093042.0
007      
ta
008      
190405s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12890-017-0563-7 $2 doi
035    __
$a (PubMed)29282032
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a McLaughlin, Vallerie V $u University of Michigan Health System, 1011 Cornwell Pl, Ann Arbor, 48104, USA. vmclaugh@med.umich.edu.
245    10
$a Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study / $c VV. McLaughlin, P. Jansa, JE. Nielsen-Kudsk, M. Halank, G. Simonneau, E. Grünig, S. Ulrich, S. Rosenkranz, MA. Gómez Sánchez, T. Pulido, J. Pepke-Zaba, JA. Barberá, MM. Hoeper, JL. Vachiéry, I. Lang, F. Carvalho, C. Meier, K. Mueller, S. Nikkho, AM. D'Armini,
520    9_
$a BACKGROUND: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH. METHODS: We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted therapy (n = 84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking distance (6MWD) as exploratory efficacy endpoints. RESULTS: In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean ± standard deviation 6MWD had increased by 33 ± 42 m at Week 12 with no clinically relevant differences between the switched and treatment-naïve subgroups. CONCLUSIONS: Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were switched from other PAH-targeted therapies. No new safety signals were observed. TRIAL REGISTRATION: ClinicalTrials.org NCT01784562 . Registered February 4, 2013.
650    _2
$a senioři $7 D000368
650    _2
$a antihypertenziva $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000959
650    _2
$a chronická nemoc $7 D002908
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x farmakoterapie $x patofyziologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011720
650    _2
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011743
650    _2
$a synkopa $x chemicky indukované $7 D013575
650    _2
$a tromboembolie $x komplikace $7 D013923
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jansa, Pavel $u Cardiology and Angiology Department, General University Hospital, Prague, Czech Republic.
700    1_
$a Nielsen-Kudsk, Jens E $u Department of Cardiological Medicine, Aarhus University, Aarhus, Denmark.
700    1_
$a Halank, Michael $u University Hospital Dresden, Dresden, Germany.
700    1_
$a Simonneau, Gérald $u Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and INSERM Unité 999, Paris, France.
700    1_
$a Grünig, Ekkehard $u Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany.
700    1_
$a Ulrich, Silvia $u Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Rosenkranz, Stephan $u Department III of Internal Medicine, Cologne University Heart Center, Cologne, Germany.
700    1_
$a Gómez Sánchez, Miguel A $u Unidad de I. Cardiaca e Hipertensión Pulmonar, Hospital Universitario 12 de Octubre, Madrid, Spain.
700    1_
$a Pulido, Tomás $u Instituto Nacional de Cardiología, Mexico City, Mexico.
700    1_
$a Pepke-Zaba, Joanna $u National Pulmonary Vascular Diseases Unit, Papworth Hospital, Cambridge, UK.
700    1_
$a Barberá, Joan Albert $u Department of Pulmonary Medicine, Hospital Clínic-IDIBAPS, University of Barcelona, and Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain.
700    1_
$a Hoeper, Marius M $u Clinic for Respiratory Medicine, Hannover Medical School, Hannover, Germany.
700    1_
$a Vachiéry, Jean-Luc $u Département de Cardiologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
700    1_
$a Lang, Irene $u Allgemeines Krankenhaus der Stadt Wien, Medizinische Universität Wien, Wien, Austria.
700    1_
$a Carvalho, Francine $u Global Development, Bayer SA, São Paulo, Brazil.
700    1_
$a Meier, Christian $u Global Medical Affairs, Bayer AG, Berlin, Germany.
700    1_
$a Mueller, Katharina $u Bayer AG, Wuppertal, Germany.
700    1_
$a Nikkho, Sylvia $u Global Clinical Development, Bayer AG, Berlin, Germany.
700    1_
$a D'Armini, Andrea M $u Division of Cardiothoracic Surgery, Foundation "IRCCS Policlinico San Matteo", University of Pavia School of Medicine, Pavia, Italy.
773    0_
$w MED00008206 $t BMC pulmonary medicine $x 1471-2466 $g Roč. 17, č. 1 (2017), s. 216
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29282032 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411093059 $b ABA008
999    __
$a ok $b bmc $g 1392271 $s 1051266
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 17 $c 1 $d 216 $e 20171228 $i 1471-2466 $m BMC pulmonary medicine $n BMC Pulm Med $x MED00008206
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace